ECCO (IBD) 2019 Conference Review, reviewed by Professor Rupert Leong

In this review:

Vedolizumab vs adalimumab in active UC
Withdrawal of thiopurines in CD treated with scheduled adalimumab maintenance
Ustekinumab induction therapy and endoscopic/histological healing in UC
Efficacy and safety of ustekinumab as maintenance in UC
Efficacy of ustekinumab in moderate-to-severe UC
Endoscopic and deep remission at 1 year prevents disease progression in early CD
Identifying the true prevalence of IBD: The Lothian IBD Registry

Please login below to download this issue (PDF)